XXXX induced apoptotic and necrotic chromatin changes in rat myeloid leukemia cells.

@entity137 @entity419 @entity39 @entity1500 @entity1499 @entity309
OBJECTIVE: It was tested as to why low-dose @entity1499 ( @entity1500 ) effective against @entity309 poses considerable health risk at higher doses. METHODS: The tumorigenic potential of My1/De blast cells was followed by cytology and by the kinetics of @entity419 uptake. The @entity137 of @entity1500 on chromatin condensation was compared to predictive normal intermediates of chromosome condensation in control cells. RESULTS: @entity1500 below 0.1    g/ml did not cause visible changes in interphase chromatin structure. At its lowest toxic concentration (0.1    g/ml) chromatin margination was confined to the outer edge of the nucleus. Between 0.1 and 5    g/ml concentrations apoptotic chromatin shrinkage correlated with the dose of @entity1500 . Apoptosis was exerted in early S phase excluding the mitotic effect. At higher @entity1500 concentrations (>10    g/ml) necrotic disruption and expansion took place. The lowest necrotic concentration (10    g/ml) was close to highest apoptotic @entity1500 concentration (5    g/ml). CONCLUSIONS: The switch from apoptosis to @entity39 taking place within a narrow concentration range supports the notion of a narrow therapeutic spectrum. Chromatin changes are early markers of genotoxicity at much lower concentrations than citogenetic changes in properly chosen sensitive cells.
